Elevance Health's Q4 2024: Conflicting Signals on Medicare Advantage Guidance and Cyberattack Impact
Thursday, Jan 23, 2025 5:54 pm ET
1min read Membership and Revenue Trends:
- Elevance Health reported a total of 45.7 million members at the conclusion of 2024, marking a decrease of 1.1 million year-over-year, driven by Medicaid redeterminations and changes in its geographic footprint. However, this was partially offset by growth in employer group fee-based offerings and ACA health plan products.
- The company generated $175.2 billion in total operating revenue for 2024, up approximately 3% from the prior year, reflecting premium rate adjustments and expanding Carelon businesses, despite lower Medicaid membership.
- The revenue growth was supported by acquisitions in pharmacy services and home health, which align with its enterprise growth strategy.
Medicaid and Medicare Cost Trends:
- Medicaid cost trends remained elevated, consistent with the outlook shared in the previous quarter, impacting the benefit expense ratio.
- In the Medicare segment, benefit reductions and market exits in 2024 provided a strong foundation for profitable growth in 2025, with anticipated Medicare Advantage membership growth in the range of 7% to 9%.
- The company's strategy to enhance partnerships with care providers and align data sharing is aimed at improving care quality, efficiency, and administrative burdens.
Commercial Business Growth:
- Elevance Health's commercial businesses performed well in 2024, with the integrated medical and pharmacy offering resonating in the market, leading to 18 new national accounts and strong retention rates.
- The individual exchange business experienced more than 30% growth in 2024, driven by innovative and affordable products.
- This growth is attributed to the company's ability to deliver compelling value in competitive market segments and strong employer group fee-based growth.
Capital Allocation and Shareholder Returns:
- Elevance Health opportunistically repurchased 0.5 million shares for a total of $1.8 billion in the fourth quarter, exceeding its initial forecast, and reported $2.9 billion in full-year repurchases.
- The Board of Directors approved a 5% increase in the quarterly dividend to $1.71 per share, marking the 14th consecutive annual increase.
- The company remains committed to returning capital to shareholders while investing in strategic initiatives, positioning itself for long-term growth and value creation.
- Elevance Health reported a total of 45.7 million members at the conclusion of 2024, marking a decrease of 1.1 million year-over-year, driven by Medicaid redeterminations and changes in its geographic footprint. However, this was partially offset by growth in employer group fee-based offerings and ACA health plan products.
- The company generated $175.2 billion in total operating revenue for 2024, up approximately 3% from the prior year, reflecting premium rate adjustments and expanding Carelon businesses, despite lower Medicaid membership.
- The revenue growth was supported by acquisitions in pharmacy services and home health, which align with its enterprise growth strategy.
Medicaid and Medicare Cost Trends:
- Medicaid cost trends remained elevated, consistent with the outlook shared in the previous quarter, impacting the benefit expense ratio.
- In the Medicare segment, benefit reductions and market exits in 2024 provided a strong foundation for profitable growth in 2025, with anticipated Medicare Advantage membership growth in the range of 7% to 9%.
- The company's strategy to enhance partnerships with care providers and align data sharing is aimed at improving care quality, efficiency, and administrative burdens.
Commercial Business Growth:
- Elevance Health's commercial businesses performed well in 2024, with the integrated medical and pharmacy offering resonating in the market, leading to 18 new national accounts and strong retention rates.
- The individual exchange business experienced more than 30% growth in 2024, driven by innovative and affordable products.
- This growth is attributed to the company's ability to deliver compelling value in competitive market segments and strong employer group fee-based growth.
Capital Allocation and Shareholder Returns:
- Elevance Health opportunistically repurchased 0.5 million shares for a total of $1.8 billion in the fourth quarter, exceeding its initial forecast, and reported $2.9 billion in full-year repurchases.
- The Board of Directors approved a 5% increase in the quarterly dividend to $1.71 per share, marking the 14th consecutive annual increase.
- The company remains committed to returning capital to shareholders while investing in strategic initiatives, positioning itself for long-term growth and value creation.
Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.
